Fallbericht
Ixazomib – lenalidomide – dexamethason in heavily pretreated multiple myeloma patients – case reports
Klinicka onkologie · 2023
DOI: 10.48095/ccko2023150 ↗Kurz gefasst
Fallbericht in der Zeitschrift Klinicka onkologie, 2023. Verfasst von M Štork. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Multiple MyelomaHumansLenalidomideDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsProteasome InhibitorsBoron CompoundsGlycine
Stichwörter der Autor:innen
Kahler-Pick lawMultiple myelomaixazomibleukaemialeukemiaplasmacytomaretreatment
Substanzen
LenalidomideDexamethasoneProteasome InhibitorsixazomibBoron CompoundsGlycine
Zitieren
APA
Štork, M. (2023). Ixazomib – lenalidomide – dexamethason in heavily pretreated multiple myeloma patients – case reports. Klinicka onkologie. https://doi.org/10.48095/ccko2023150
Vancouver
Štork M. Ixazomib – lenalidomide – dexamethason in heavily pretreated multiple myeloma patients – case reports. Klinicka onkologie. 2023. doi:10.48095/ccko2023150
BibTeX
@article{tork2023,
author = {Štork, M},
title = {Ixazomib – lenalidomide – dexamethason in heavily pretreated multiple myeloma patients – case reports},
journal = {Klinicka onkologie},
year = {2023},
doi = {10.48095/ccko2023150}
}
EUVIMED